USFDA cautions Aurobindo Pharma's oral solids formulation facility of regulatory action

According to USFDA's definitions, OAI means "objectionable conditions
were found and regulatory administrative sanctions by FDA are
indicated" during inspections. The company said that it believes that
this OAI classification will not have any material impact on the
existing revenues or the supplies to its US business at this juncture.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-cautions-aurobindo-pharmas-oral-solids-formulation-facility-of-regulatory-action/articleshow/73761421.cms

Comments

Popular posts from this blog

The Scroll and the Revolution: The Dilemmas of Writing about the Jews of Cuba

MAHE Manipal Research Fellow Jobs – Biotech / Mol Bio / Microbiology Apply

The Right Tool for the Job: Foreign Policy Effectiveness and Nuclear Proliferation